雷帕鸣西罗莫司片的说明书

Instructions for sirolimus tablets

Rapamune sirolimus tablets are an oral drug with the trade name Rapamune. As early as 1989, it was studied as a new and highly effective immunosuppressant for the anti-rejection effect of organ transplants. It is currently mainly used to treat patients aged 13 or above who have received kidney transplants to prevent organ rejection. Recommended for use in combination with cyclosporine and corticosteroids.

Rapamin Sirolimus Tablets Usage and Dosage:

Rapamin is taken orally, once a day. To reduce differences in drug absorption, patients should choose to take the drug regularly with or without food. Tablets should not be broken or chewed. It should be started as soon as possible after transplantation. For new transplant recipients, the loading dose that should be taken for the first time is three times the maintenance dose. The recommended loading dose for kidney transplant patients is 6 mg and the maintenance dose is 2 mg/day. During the treatment process, patients need to monitor the blood concentration of therapeutic drugs.

Because the safety and efficacy of rapamin have not been established in children under 13 years of age, its use is not recommended.

Precautions for Rapamin Sirolimus Tablets:

1. Anaphylaxis/hypersensitivity reaction: Anaphylaxis, angioedema, exfoliative dermatitis and hypersensitivity vasculitis have been reported. Patients with the above situations need to contact their doctor in time.

2. Infection: Immunosuppression may also increase the risk of infection, including activation of latent viral infections (including BK virus-related nephropathy), fatal infections, and sepsis. Pneumocystis jiroveci pneumonia (PCP) should be prophylactically treated 1 year after transplantation, and cytomegalovirus (CMV) should be prophylactic 3 months after transplantation.

3. Hyperlipidemia: May increase blood lipids (cholesterol and triglycerides). Monitoring is required during treatment, and patients with hyperlipidemia should use it with caution.

4. Interstitial lung disease: Cases (some fatal) of interstitial lung disease (such as pneumonia, organizing pneumonia, bronchiolitis obliterans, pulmonary fibrosis, etc.) have been observed; may be related to pulmonary hypertension (including pulmonary hypertension). Relief may occur by reducing the dose or discontinuing treatment. 

The above is an introduction to the contents of the instructions for sirolimus. Patients must follow the doctor's instructions carefully during the medication.

Recommended related hot articles: /newsDetail/80094.html